Real-World Evidence Global Market Report 2026

Real-world evidence (RWE) encompasses clinical findings and healthcare outcomes obtained from real-world data sources, including electronic health records, insurance claims databases, patient registries, and wearable health technologies. It is utilized to evaluate treatment performance, safety profiles, and healthcare resource utilization in routine clinical environments beyond the confines of controlled clinical studies. By examining extensive longitudinal patient datasets, it facilitates evidence development for regulatory assessments, clinical investigations, and healthcare planning initiatives.

The primary components of real-world evidence consist of services, data sets, and analytics platforms. Services are specialized offerings that assist organizations in gathering, evaluating, and interpreting real-world healthcare data to support evidence generation. These solutions are implemented through cloud-based and on-premises deployment models. They are utilized for drug development and approval, post-market surveillance, market access and reimbursement, clinical and regulatory decision-making, and pharmacovigilance, serving end users such as pharmaceutical and biotechnology companies, healthcare providers, contract research organizations, healthcare payers, government and regulatory agencies, and medical device companies.

Tariffs are influencing the real-world evidence market by increasing the cost of imported cloud infrastructure hardware, data storage systems, and advanced analytics technologies required for large-scale healthcare data processing. This is affecting the deployment of RWE platforms, particularly in import-dependent regions such as Asia-Pacific and Latin America, and slowing the expansion of healthcare data integration and analytics capabilities. Analytics platforms and cloud-based deployment models are the most affected segments due to their reliance on global software-hardware ecosystems. However, tariffs are also encouraging the development of regional data infrastructure, localization of analytics platforms, and increased investment in domestic healthcare data ecosystems, which is expected to strengthen long-term data sovereignty and innovation.

The real-world evidence market size has grown rapidly in recent years. It will grow from $4.33 billion in 2025 to $5.14 billion in 2026 at a compound annual growth rate (CAGR) of 18.7%. The growth in the historic period can be attributed to increasing digitization of healthcare records and electronic health record adoption, rising use of insurance claims data for healthcare analytics, growth of clinical research demand for post-market surveillance, expansion of patient registries across disease areas, growing regulatory acceptance of real world data in decision making.

The real-world evidence market size is expected to see rapid growth in the next few years. It will grow to $10.3 billion in 2030 at a compound annual growth rate (CAGR) of 19.0%. The growth in the forecast period can be attributed to increasing integration of AI and machine learning in real world evidence generation, rising adoption of wearable and remote monitoring devices for continuous data collection, growing demand for personalized and precision medicine insights, expansion of cloud-based healthcare analytics ecosystems, increasing use of predictive and prescriptive analytics in regulatory and reimbursement decisions. Major trends in the forecast period include increasing adoption of AI-driven real world evidence analytics platforms for clinical decision support, rising integration of wearable and remote patient monitoring data into rwe generation systems, growing use of predictive analytics for post-market surveillance and drug safety monitoring, expansion of cloud-based real world data platforms for large-scale healthcare data aggregation, increasing utilization of machine learning models for regulatory-grade evidence generation.

The increasing adoption of precision medicine is expected to drive the growth of the real-world evidence market going forward. Precision medicine is a medical approach that tailors treatment based on individual patient characteristics such as genetics, biomarkers, and disease phenotypes. The demand for precision medicine is increasing due to advancements in biomarker identification and molecular diagnostics, which enable more accurate classification of diseases and improved selection of targeted therapies. Real-world evidence, derived from electronic health records, registries, claims data, and wearable devices, supports precision medicine by demonstrating how treatments perform across diverse populations and highlighting variations in response, safety, and outcomes that help personalize therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant increase compared to six approvals in 2022. Therefore, the rising adoption of precision medicine is driving the growth of the real-world evidence market.

Leading companies operating in the real-world evidence market are focusing on developing innovative solutions, such as integrated real-world data analytics platforms, to enhance patient-centered clinical research, regulatory decision-making, and drug development efficiency. Integrated real-world data analytics platforms are advanced digital systems that aggregate and analyze diverse healthcare data sources such as electronic health records, patient-reported outcomes, wearable device data, and clinical trial datasets, enabling researchers to generate actionable insights beyond traditional controlled clinical trials. For example, in September 2023, Maxis Clinical Sciences, a US-based life sciences services company, launched Real-World Evidence Solutions designed to support patient-centered clinical research and drug development. The solution integrates diverse real-world data sources, including patient-reported outcomes and wearable device data, to improve data quality and patient engagement. It enables applications such as personalized medicine by supporting targeted treatment strategies, regulatory submissions by strengthening evidence packages, health economics and outcomes research (HEOR) by evaluating treatment cost-effectiveness, and drug repurposing by identifying new therapeutic uses for existing medicines.

In December 2023, BC Platforms AG, a Switzerland-based healthcare data management and analytics company, acquired Medexprim SAS for an undisclosed amount. Through this acquisition, BC Platforms AG aimed to strengthen its global real-world data (RWD) and real-world evidence (RWE) capabilities by integrating Medexprim SAS's multimodal clinical and imaging datasets sourced from European hospitals, thereby expanding its capacity to support precision medicine, accelerate drug development, and deliver enhanced data-driven insights for life sciences organizations. Medexprim SAS is a France-based healthcare data company specializing in providing regulatory-grade real-world data (RWD) and real-world evidence (RWE).

Major companies operating in the real-world evidence market are Optum Inc.; Oracle Corporation; IQVIA Holdings Inc.; ICON plc; Syneos Health Inc.; PPD (Thermo Fisher Scientific); Flatiron Health; Veeva Systems Inc.; Fortrea Holdings Inc.; Clarivate Plc; SAS Institute Inc.; Cegedim SA; Veradigm Inc.; Medpace Holdings Inc.; Merative L.P.; Parexel International; HealthCore Inc.; Datavant Inc.; oncertAI LLC; Komodo Health Inc.; Aetion Inc.; Truveta Inc.; HealthVerity Inc.; Evidation Health Inc.; OM1 Inc.; COTA Inc.; Cytel Inc.

North America was the largest region in the real-world evidence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the real-world evidence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the real-world evidence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The real-world evidence market includes revenues earned by entities by providing services such as data collection and aggregation, data analytics and interpretation, observational study design, evidence generation and synthesis, regulatory consulting support, healthcare database management, and software platforms for real-world data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The real-world evidence market research report is one of a series of new reports from The Business Research Company that provides real-world evidence market statistics, including real-world evidence industry global market size, regional shares, competitors with a real-world evidence market share, detailed real-world evidence market segments, market trends and opportunities, and any further data you may need to thrive in the real-world evidence industry. This real-world evidence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Real-World Evidence Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses real-world evidence market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for real-world evidence ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The real-world evidence market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Component: Services; Data Sets; Analytics Platforms
• 2) By Deployment Mode: Cloud Based; On Premises
• 3) By Application: Drug Development And Approval; Post Market Surveillance; Market Access And Reimbursement; Clinical And Regulatory Decision Making; Pharmacovigilance
• 4) By End User: Pharmaceutical And Biotechnology Companies; Healthcare Providers; Contract Research Organizations; Healthcare Payers; Government And Regulatory Organizations; Medical Device Companies
• Subsegments:
• 1) By Services: Consulting Services; Data Management Services; Data Collection Services; Regulatory Compliance Services; Clinical Research Support Services; Real World Data Integration Services; Evidence Generation Services
• 2) By Data Sets: Claims Data Sets; Electronic Health Records Data Sets; Patient Registry Data Sets; Patient Reported Outcome Data Sets; Wearable Device Data Sets; Genomic Data Sets; Pharmacy And Prescription Data Sets
• 3) By Analytics Platforms: Descriptive Analytics Platforms; Predictive Analytics Platforms; Prescriptive Analytics Platforms; Data Visualization Platforms; Machine Learning Based Analytics Platforms; Artificial Intelligence Driven Analytics Platforms; Real Time Analytics Platforms
• Companies Mentioned: Optum Inc.; Oracle Corporation; IQVIA Holdings Inc.; ICON plc; Syneos Health Inc.; PPD (Thermo Fisher Scientific); Flatiron Health; Veeva Systems Inc.; Fortrea Holdings Inc.; Clarivate Plc; SAS Institute Inc.; Cegedim SA; Veradigm Inc.; Medpace Holdings Inc.; Merative L.P.; Parexel International; HealthCore Inc.; Datavant Inc.; oncertAI LLC; Komodo Health Inc.; Aetion Inc.; Truveta Inc.; HealthVerity Inc.; Evidation Health Inc.; OM1 Inc.; COTA Inc.; Cytel Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.